Matthew Plunkett Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Matthew Plunkett.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Matthew Plunkett. Matthew Plunkett is EVP, Chief Business Officer in CTI BIOPHARMA CORP ($CTIC) and EVP, Corporate Development in CTI BIOPHARMA CORP ($CTIC) and Chief Financial Officer in Nkarta, Inc. ($NKTX).
Latest Insider Trading Transactions of Matthew Plunkett
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 13 2020 | NKTX | Nkarta, Inc. | Plunkett Matthew | Chief Financial Off ... | Option Exercise | A | 18.00 | 77,800 | 1,400,400 | 77,800 | |
Jul 13 2020 | NKTX | Nkarta, Inc. | Plunkett Matthew | Chief Financial Off ... | Option Exercise | A | 18.00 | 77,800 | 1,400,400 | 77,800 | |
Mar 06 2017 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Option Exercise | A | 4.33 | 60,000 | 259,800 | 60,000 | |
Mar 23 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Payment of Exercise | F | 0.55 | 63,874 | 35,016 | 526,210 | 590.1 K to 526.2 K (-10.82 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.60 | 900 | 536 | 590,084 | 591 K to 590.1 K (-0.15 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.60 | 1,220 | 726 | 590,984 | 592.2 K to 591 K (-0.21 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 500 | 297 | 592,204 | 592.7 K to 592.2 K (-0.08 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 1,100 | 652 | 592,704 | 593.8 K to 592.7 K (-0.19 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 200 | 118 | 593,804 | 594 K to 593.8 K (-0.03 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 700 | 414 | 594,004 | 594.7 K to 594 K (-0.12 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 700 | 413 | 594,704 | 595.4 K to 594.7 K (-0.12 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 844 | 497 | 595,404 | 596.2 K to 595.4 K (-0.14 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 1,500 | 882 | 596,248 | 597.7 K to 596.2 K (-0.25 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 636 | 373 | 597,748 | 598.4 K to 597.7 K (-0.11 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 400 | 234 | 598,384 | 598.8 K to 598.4 K (-0.07 %) |
Mar 04 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 0.59 | 1,300 | 761 | 598,784 | 600.1 K to 598.8 K (-0.22 %) |
Feb 05 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.18 | 300 | 353 | 600,084 | 600.4 K to 600.1 K (-0.05 %) |
Feb 05 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.17 | 700 | 819 | 600,384 | 601.1 K to 600.4 K (-0.12 %) |
Feb 05 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.16 | 600 | 696 | 601,084 | 601.7 K to 601.1 K (-0.10 %) |
Feb 05 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.16 | 3,000 | 3,465 | 601,684 | 604.7 K to 601.7 K (-0.50 %) |
Feb 05 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.15 | 5,000 | 5,750 | 604,684 | 609.7 K to 604.7 K (-0.82 %) |
Feb 05 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.14 | 400 | 456 | 609,684 | 610.1 K to 609.7 K (-0.07 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.26 | 200 | 252 | 610,084 | 610.3 K to 610.1 K (-0.03 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.25 | 600 | 750 | 610,284 | 610.9 K to 610.3 K (-0.10 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.24 | 202 | 250 | 610,884 | 611.1 K to 610.9 K (-0.03 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.24 | 300 | 371 | 611,086 | 611.4 K to 611.1 K (-0.05 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.23 | 800 | 984 | 611,386 | 612.2 K to 611.4 K (-0.13 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.22 | 1,700 | 2,074 | 612,186 | 613.9 K to 612.2 K (-0.28 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.21 | 1,900 | 2,299 | 613,886 | 615.8 K to 613.9 K (-0.31 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.21 | 800 | 964 | 615,786 | 616.6 K to 615.8 K (-0.13 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.20 | 1,898 | 2,278 | 616,586 | 618.5 K to 616.6 K (-0.31 %) |
Jan 06 2016 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Sell | S | 1.20 | 1,600 | 1,912 | 618,484 | 620.1 K to 618.5 K (-0.26 %) |
Dec 23 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Option Exercise | A | 1.24 | 1,400,000 | 1,736,000 | 1,400,000 | |
Dec 23 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Option Exercise | D | 0.00 | 253,438 | 0 | 0 | |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.01 | 200 | 202 | 620,084 | 620.3 K to 620.1 K (-0.03 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.01 | 100 | 101 | 620,284 | 620.4 K to 620.3 K (-0.02 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 4,500 | 4,500 | 620,384 | 624.9 K to 620.4 K (-0.72 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 100 | 100 | 624,884 | 625 K to 624.9 K (-0.02 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 200 | 200 | 624,984 | 625.2 K to 625 K (-0.03 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 300 | 300 | 625,184 | 625.5 K to 625.2 K (-0.05 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 100 | 100 | 625,484 | 625.6 K to 625.5 K (-0.02 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 100 | 100 | 625,584 | 625.7 K to 625.6 K (-0.02 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.00 | 600 | 597 | 625,684 | 626.3 K to 625.7 K (-0.10 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 0.99 | 200 | 199 | 626,284 | 626.5 K to 626.3 K (-0.03 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 0.99 | 1,100 | 1,094 | 626,484 | 627.6 K to 626.5 K (-0.18 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 0.99 | 200 | 199 | 627,584 | 627.8 K to 627.6 K (-0.03 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 0.99 | 200 | 198 | 627,784 | 628 K to 627.8 K (-0.03 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 0.99 | 600 | 594 | 627,984 | 628.6 K to 628 K (-0.10 %) |
Dec 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 0.99 | 1,500 | 1,485 | 628,584 | 630.1 K to 628.6 K (-0.24 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.40 | 1,400 | 1,960 | 630,084 | 631.5 K to 630.1 K (-0.22 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.40 | 100 | 140 | 631,484 | 631.6 K to 631.5 K (-0.02 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.39 | 1,100 | 1,529 | 631,584 | 632.7 K to 631.6 K (-0.17 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.39 | 200 | 277 | 632,684 | 632.9 K to 632.7 K (-0.03 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.38 | 3,500 | 4,830 | 632,884 | 636.4 K to 632.9 K (-0.55 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.38 | 1,800 | 2,475 | 636,384 | 638.2 K to 636.4 K (-0.28 %) |
Nov 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.37 | 1,900 | 2,603 | 638,184 | 640.1 K to 638.2 K (-0.30 %) |
Oct 07 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.53 | 584 | 894 | 640,084 | 640.7 K to 640.1 K (-0.09 %) |
Oct 07 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.53 | 1,100 | 1,678 | 640,668 | 641.8 K to 640.7 K (-0.17 %) |
Oct 07 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.52 | 6,916 | 10,512 | 641,768 | 648.7 K to 641.8 K (-1.07 %) |
Oct 07 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.52 | 1,400 | 2,121 | 648,684 | 650.1 K to 648.7 K (-0.22 %) |
Oct 01 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.43 | 8,394 | 12,003 | 650,084 | 658.5 K to 650.1 K (-1.27 %) |
Oct 01 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.43 | 100 | 143 | 658,478 | 658.6 K to 658.5 K (-0.02 %) |
Oct 01 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.42 | 9,092 | 12,911 | 658,578 | 667.7 K to 658.6 K (-1.36 %) |
Oct 01 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.42 | 5,108 | 7,244 | 667,670 | 672.8 K to 667.7 K (-0.76 %) |
Oct 01 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.41 | 52,306 | 73,751 | 672,778 | 725.1 K to 672.8 K (-7.21 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.61 | 660 | 1,063 | 725,084 | 725.7 K to 725.1 K (-0.09 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.61 | 1,390 | 2,231 | 725,744 | 727.1 K to 725.7 K (-0.19 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.60 | 14,400 | 23,040 | 727,134 | 741.5 K to 727.1 K (-1.94 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.60 | 1,500 | 2,393 | 741,534 | 743 K to 741.5 K (-0.20 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.59 | 16,400 | 26,076 | 743,034 | 759.4 K to 743 K (-2.16 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.59 | 7,000 | 11,095 | 759,434 | 766.4 K to 759.4 K (-0.91 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.58 | 5,330 | 8,421 | 766,434 | 771.8 K to 766.4 K (-0.69 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.58 | 1,000 | 1,575 | 771,764 | 772.8 K to 771.8 K (-0.13 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.57 | 1,700 | 2,669 | 772,764 | 774.5 K to 772.8 K (-0.22 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.56 | 800 | 1,248 | 774,464 | 775.3 K to 774.5 K (-0.10 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.55 | 800 | 1,240 | 775,264 | 776.1 K to 775.3 K (-0.10 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.55 | 600 | 927 | 776,064 | 776.7 K to 776.1 K (-0.08 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.54 | 289 | 445 | 776,664 | 777 K to 776.7 K (-0.04 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.54 | 100 | 154 | 776,953 | 777.1 K to 777 K (-0.01 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.53 | 6,899 | 10,555 | 777,053 | 784 K to 777.1 K (-0.88 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.53 | 200 | 306 | 783,952 | 784.2 K to 784 K (-0.03 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.53 | 13,201 | 20,132 | 784,152 | 797.4 K to 784.2 K (-1.66 %) |
Sep 25 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.52 | 3,600 | 5,472 | 797,353 | 801 K to 797.4 K (-0.45 %) |
Sep 23 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Grant | A | 0.00 | 151,739 | 0 | 800,953 | 649.2 K to 801 K (+23.37 %) |
Sep 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.55 | 1,800 | 2,790 | 649,214 | 651 K to 649.2 K (-0.28 %) |
Sep 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.54 | 1,000 | 1,540 | 651,014 | 652 K to 651 K (-0.15 %) |
Sep 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.54 | 1,700 | 2,610 | 652,014 | 653.7 K to 652 K (-0.26 %) |
Sep 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.53 | 5,500 | 8,415 | 653,714 | 659.2 K to 653.7 K (-0.83 %) |
Sep 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Payment of Exercise | F | 1.52 | 12,526 | 19,040 | 659,214 | 671.7 K to 659.2 K (-1.86 %) |
Aug 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.85 | 100 | 185 | 671,740 | 671.8 K to 671.7 K (-0.01 %) |
Aug 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.85 | 5,000 | 9,225 | 671,840 | 676.8 K to 671.8 K (-0.74 %) |
Aug 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.84 | 4,900 | 9,016 | 676,840 | 681.7 K to 676.8 K (-0.72 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.98 | 200 | 396 | 681,740 | 681.9 K to 681.7 K (-0.03 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.98 | 2,256 | 4,456 | 681,940 | 684.2 K to 681.9 K (-0.33 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.97 | 444 | 875 | 684,196 | 684.6 K to 684.2 K (-0.06 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.97 | 700 | 1,376 | 684,640 | 685.3 K to 684.6 K (-0.10 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.96 | 1,000 | 1,960 | 685,340 | 686.3 K to 685.3 K (-0.15 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.95 | 400 | 780 | 686,340 | 686.7 K to 686.3 K (-0.06 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.95 | 1,200 | 2,334 | 686,740 | 687.9 K to 686.7 K (-0.17 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.93 | 1,700 | 3,281 | 687,940 | 689.6 K to 687.9 K (-0.25 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.93 | 100 | 193 | 689,640 | 689.7 K to 689.6 K (-0.01 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.93 | 700 | 1,348 | 689,740 | 690.4 K to 689.7 K (-0.10 %) |
Jul 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.92 | 1,300 | 2,496 | 690,440 | 691.7 K to 690.4 K (-0.19 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.08 | 100 | 208 | 691,740 | 691.8 K to 691.7 K (-0.01 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.08 | 200 | 415 | 691,840 | 692 K to 691.8 K (-0.03 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.07 | 3,700 | 7,659 | 692,040 | 695.7 K to 692 K (-0.53 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.07 | 100 | 207 | 695,740 | 695.8 K to 695.7 K (-0.01 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.06 | 2,400 | 4,944 | 695,840 | 698.2 K to 695.8 K (-0.34 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.06 | 1,000 | 2,055 | 698,240 | 699.2 K to 698.2 K (-0.14 %) |
Jun 05 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.05 | 2,500 | 5,125 | 699,240 | 701.7 K to 699.2 K (-0.36 %) |
May 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.87 | 600 | 1,119 | 701,740 | 702.3 K to 701.7 K (-0.09 %) |
May 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.86 | 3,000 | 5,580 | 702,340 | 705.3 K to 702.3 K (-0.43 %) |
May 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.86 | 2,700 | 5,009 | 705,340 | 708 K to 705.3 K (-0.38 %) |
May 04 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.85 | 3,700 | 6,845 | 708,040 | 711.7 K to 708 K (-0.52 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.92 | 300 | 576 | 711,740 | 712 K to 711.7 K (-0.04 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.92 | 100 | 192 | 712,040 | 712.1 K to 712 K (-0.01 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.91 | 1,400 | 2,674 | 712,140 | 713.5 K to 712.1 K (-0.20 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.91 | 100 | 191 | 713,540 | 713.6 K to 713.5 K (-0.01 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.90 | 1,600 | 3,040 | 713,640 | 715.2 K to 713.6 K (-0.22 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.90 | 100 | 190 | 715,240 | 715.3 K to 715.2 K (-0.01 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.89 | 1,400 | 2,646 | 715,340 | 716.7 K to 715.3 K (-0.20 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.89 | 2,000 | 3,770 | 716,740 | 718.7 K to 716.7 K (-0.28 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.88 | 1,900 | 3,572 | 718,740 | 720.6 K to 718.7 K (-0.26 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.88 | 769 | 1,442 | 720,640 | 721.4 K to 720.6 K (-0.11 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.87 | 5,300 | 9,911 | 721,409 | 726.7 K to 721.4 K (-0.73 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.87 | 800 | 1,492 | 726,709 | 727.5 K to 726.7 K (-0.11 %) |
Apr 08 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.86 | 800 | 1,488 | 727,509 | 728.3 K to 727.5 K (-0.11 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.98 | 2,330 | 4,613 | 728,309 | 730.6 K to 728.3 K (-0.32 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.98 | 2,216 | 4,377 | 730,639 | 732.9 K to 730.6 K (-0.30 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.97 | 5,184 | 10,212 | 732,855 | 738 K to 732.9 K (-0.70 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.97 | 11,700 | 22,991 | 738,039 | 749.7 K to 738 K (-1.56 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.96 | 28,197 | 55,266 | 749,739 | 777.9 K to 749.7 K (-3.62 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.96 | 7,903 | 15,450 | 777,936 | 785.8 K to 777.9 K (-1.01 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 1.95 | 1,600 | 3,120 | 785,839 | 787.4 K to 785.8 K (-0.20 %) |
Mar 24 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Payment of Exercise | F | 1.94 | 59,784 | 115,682 | 787,439 | 847.2 K to 787.4 K (-7.06 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.44 | 1,100 | 2,684 | 847,223 | 848.3 K to 847.2 K (-0.13 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.44 | 200 | 487 | 848,323 | 848.5 K to 848.3 K (-0.02 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.43 | 600 | 1,458 | 848,523 | 849.1 K to 848.5 K (-0.07 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.43 | 200 | 485 | 849,123 | 849.3 K to 849.1 K (-0.02 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.42 | 2,800 | 6,776 | 849,323 | 852.1 K to 849.3 K (-0.33 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.42 | 300 | 725 | 852,123 | 852.4 K to 852.1 K (-0.04 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.41 | 1,700 | 4,097 | 852,423 | 854.1 K to 852.4 K (-0.20 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.41 | 1,000 | 2,405 | 854,123 | 855.1 K to 854.1 K (-0.12 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.40 | 1,800 | 4,320 | 855,123 | 856.9 K to 855.1 K (-0.21 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.40 | 1,100 | 2,635 | 856,923 | 858 K to 856.9 K (-0.13 %) |
Mar 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.39 | 1,200 | 2,868 | 858,023 | 859.2 K to 858 K (-0.14 %) |
Feb 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.26 | 200 | 452 | 859,223 | 859.4 K to 859.2 K (-0.02 %) |
Feb 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.25 | 600 | 1,350 | 859,423 | 860 K to 859.4 K (-0.07 %) |
Feb 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.24 | 500 | 1,120 | 860,023 | 860.5 K to 860 K (-0.06 %) |
Feb 06 2015 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.24 | 300 | 671 | 860,523 | 860.8 K to 860.5 K (-0.03 %) |